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Background: Dyslipidemia is one of several known risk factors for coronary heart disease, a leading cause of death
in Lithuania. Blood lipid levels are influenced by multiple genetic and environmental factors. Epidemiological
studies demonstrated the impact of nutrition on lipid levels within the Lithuanian population although the role of
genetic factors for dyslipidemias has not yet been studied. The objective of this study was to assess the distribution
of the APOE, SCARB1, PPARα genotypes in the Lithuanian adult population and to determine the relationship of
these genotypes with dyslipidemia.
Methods: A cross-sectional health survey was carried out in a representative random sample of the Lithuanian
population aged 25–64 (n=1030). A variety of single-nucleotide polymorphisms (SNPs) of the APOE (rs429358 and
rs7412), SCARB1 (rs5888) and PPARα (rs1800206) genes were assessed using real-time polymerase chain reaction.
Serum lipids were determined using enzymatic methods.
Results/Principal findings: Men and women with the APOE2 genotype had the lowest level of total and low-
density lipoprotein cholesterol (LDL-C). Men with the APOE2 genotype had significantly higher levels of triglycerides
(TG) than those with the APOE3 genotype. In men, the carriers of the APOE4 genotype had higher odds ratios (OR)
of reduced (<1.0 mmol/L) high density lipoprotein cholesterol (HDL-C) levels versus APOE3 carriers (OR=1.98; 95%
CI=1.05-3.74). The odds of having elevated (>1.7 mmol/L) TG levels was significantly lower in SCARB1 genotype CT
carriers compared to men with the SCARB1 genotype CC (OR=0.50; 95% CI=0.31-0.79). In men, carriers of the PPARα
genotype CG had higher OR of elevated TG levels versus carriers of PPARα genotype CC (OR=2.67; 95% CI=1.15-
6.16). The odds of having high LDL-C levels were lower in women with the APOE2 genotype as compared to APOE3
genotype carriers (OR=0.35; 95% CI=0.22-0.57).
Conclusions/Significance: Our data suggest a gender difference in the associations between APOE, SCARB1, PPARα
genotypes and lipid levels. In men, the APOE4 genotype and PPARα genotype CG were correlated with an
atherogenic lipid profile while the SCARB1 genotype CT had an atheroprotective effect. In women, APOE2 carriers
had the lowest odds of high LDL-C.
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Table 1 Characteristics of the study population
Characteristics Men Women p value
Age, years 47.6 (0.51) 46.2 (0.43) 0.045
BMI, kg/m2 † 27.5 (0.26) 28.1 (0.22) n.s.
TC, mmol/L ‡ 5.32 (0.05) 5.30 (0.04) n.s.
LDL-C, mmol/L ‡ 3.40 (0.05) 3.21 (0.04) 0.002
HDL-C, mmol/L ‡ 1.29 (0.02) 1.43 (0.02) <0.001
LnTG, mmol/L ‡ 0,39 (0,02) 0,31 (0,02) 0.001
High TC#, n (%) 253 (59.6) 278 (46.3) <0.001
High LDL-C#, n (%) 265 (62.4) 279 (46.5) <0.001
Reduced HDL#, n (%) 105 (24.7) 138 (22.9) 0.430
Elevated TG#, n (%) 140 (33.0) 136 (22.7) <0.001
Obesity#, n (%) 105 (24.8) 151 (25.2) n.s.
Diabetesa,#, n (%) 7 (1.7) 9 (1.5) n.s.
Arterial hypertension#, n (%) 252 (59.4) 206 (34.3) <0.001
Coronary heart disease#, n (%) 36 (8.6) 35 (5.9) 0.027
† Data adjusted by age.
‡ Data adjusted by age and BMI.
# Data weighted by age.
Data are presented as mean (standard error) unless otherwise indicated.
aPhysician-diagnosed diabetes.
High TC level ≥5 mmol/L; high LDL-C level ≥3 mmol/L; reduced HDL-C level -
for men <1.0 mmol/L and for women <1.2 mmol/L; elevated TG level
>1.7 mmol/L.
Abrevations: BMI body mass index, HDL-C high density lipoprotein cholesterol,
LDL-C low density lipoprotein cholesterol, LnTG logarithmically transformed
triglycerides, TC total cholesterol.
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A high prevalence of cardiovascular diseases is a major
public health problem in Lithuania. In 2010, the age-
standardized mortality from coronary heart disease
(CHD) for Lithuanian men aged 25–64 years was 198.2
per 100 000 population and for women 44.0 per 100 000
population, while the average rate in the European
Union was 102.0 per 100 000 population for men and
24.8 per 100 000 population for women of comparable
age [1]. Dyslipidemia is one of several known risk factors
for CHD. Blood lipid levels are influenced by multiple
genetic and environmental factors [2].
Diet is the most important environmental determinant
of lipid levels. Epidemiological studies have demon-
strated some positive changes in the diet of the
Lithuanian population over the last decades. The use of
animal fats has declined, while the use of vegetable fats
and the frequency of consumption of fresh vegetables
have increased [3]. Consequently, the proportion of satu-
rated fatty acids in the daily energy intake has decreased
and the proportion of polyunsaturated fatty acids has in-
creased [4]. Positive changes in diet have contributed to
a decline in serum cholesterol levels; however, the mor-
tality rate from CHD has remained high.
Several genes were found to be associated with lipid
levels and the risk of cardiovascular diseases. Apolipo-
protein E (APOE) is a glycoprotein that plays a funda-
mental role in lipid metabolism. APOE participates in
the clearance of chylomicron remnants and very low-
density lipoprotein (VLDL) by serving as a ligand for
LDL receptors [5]. The APOE isoforms are coded by
three alleles (ε2, ε3 and ε4) resulting in six different ge-
notypes (ε2/2, ε2/3, ε2/4, ε3/3, ε3/4, and ε4/4) [6]. Many
studies assessing the role of APOE polymorphism on
plasma lipids have shown that the presence of the ε4 al-
lele is associated with elevations in LDL-C, while the
presence of ε2 is associated with decreased levels [7,8].
The human Class B Type I Scavenger Receptor (SCAR
B1) protein is a hepatic receptor with large affinity for
HDL-C [9]. After HDL-C binds to SCARB1 in the liver,
cholesterol is transferred to the cells to be released in the
bile. Some prior studies of the effect of SCARB1 ge-
notypes on HDL-C have shown conflicting results.
Studies among diabetics [10], CHD patients [11,12] and
community-based populations [13] have reported that
the SCARB1 exon 8 rs5888 (C>T) polymorphism is as-
sociated with HDL-C. However, results of other studies
have been inconsistent [14,15].
Peroxisome proliferator-activated receptor-a (PPARα)
is a member of the nuclear hormone receptor superfam-
ily of ligand-inducible transcription factors and regulates
the expression of genes involved in peroxisomal and
mitochondrial ß-oxidation pathways such as fatty acid
uptake and the catabolism of circulating triglycerides(TG) [16]. PPARα is encoded by the PPARα gene located
on chromosome 22q12-q13.1 [17]. It is expressed mainly
in tissues demonstrating high capacity for fatty acid oxi-
dation such as liver, kidney, heart, and skeletal muscle
[18,19]. In studies of healthy subjects a relationship be-
tween the PPARα L162V polymorphism and serum con-
centrations of TG [20,21] and LDL-C [22] has been
suggested.
There is a lack of data regarding the role of genetic fac-
tors for lipid levels and cardiovascular risk in Lithuania.
Our aim was therefore to assess the distribution of the
APOE, SCARB1, PPARα genotypes in the Lithuanian adult
population and to determine the relationship of these ge-
notypes with dyslipidemia.
Results
The characteristics of study subjects according to gender
are given in Table 1. An association between lipid levels
and gender was observed: men had lower levels of HDL-
C and higher levels of TG compared to women. The
prevalence of dyslipidemias was higher in men, except
for a reduction in HDL, which was similar in both men
and women. No significant differences in the frequencies
of the APOE, SCARB1 and PPARa genotypes or alleles
between men and women were observed (Table 2). Fre-
quencies of genotypes did not differ significantly from
those predicted by a Hardy-Weinberg equilibrium.
Table 2 Distribution of the APOE, SCARB1, PPARα
genotypes and frequency of the alleles (%) in the study
population
Characteristics Men Women p
valuen (%) n (%)
APOE, n.s.
ε 2/2 genotype 2 (0.5) 2 (0.3)
ε 3/2 genotype 76 (17.9) 94 (15.7)
ε 3/3 genotype 270 (63.6) 359 (59.7)
ε 4/2 genotype 13 (3.0) 21 (3.5)
ε 4/3 genotype 61 (14.5) 116 (19.3)
ε 4/4 genotype 2 (0.5) 9 (1.5)
ε3 allele 79.8 77.2 n.s.
ε2 allele 11.0 9.9
ε4 allele 9.2 12.9
SCARB1, n.s.
CC genotype 149 (35.2) 215 (35.8)
CT genotype 212 (50,0) 287 (47.8)
TT genotype 63 (14.8) 99 (16.4)
C allele 58.9 58.4 n.s.
T allele 41.1 41.6
PPARα, n.s.
CC genotype 399 (94.2) 568 (94.5)
CG genotype 25 (5.8) 32 (5.3)
GG genotype 0 1(0.2)
C allele 97.1 97.3 n.s.
G allele 2.90 2.70
Abrevations: APOE apolipoprotein E, PPARα Peroxisome proliferator-activated
receptor-alpha, SCARB1 Scavenger Receptor Class B Type 1.
Table 3 The fasting serum lipid levels in mmol/L (mean




TC LDL-C HDL-C LnTG
Mean (SE) Mean (SE) Mean (SE) Mean (SE)
MEN
APOE
APOE3 5.38 (0.06) 3.49 (0.06) 1.30 (0.03) 0.35 (0.02)
APOE2 5.03 (0.12)* 3.00 (0.11)* 1.24 (0.05) 0.47 (0.04)*
APOE4 5.56 (0.13)** 3.60 (0.12)** 1.34 (0.05) 0.44 (0.05)
SCARB 1
CC 5.30 (0.09) 3.29 (0.08) 1.26 (0.04) 0.45 (0.03)
CT 5.29 (0.07) 3.40 (0.07) 1.32 (0.03) 0.33 (0.03) #
TT 5.56 (0.13) 3.66 (0.12) # 1.27 (0.05) 0.39 (0.05)
PPARα
CC 5.35 (0.05) 3.42 (0.05) 1.30 (0.02) 0.37 (0.02)
CG 5.31 (0.21) 3.33 (0.19) 1.29 (0.09) 0.58 (0.08)# #
WOMEN
APOE
APOE3 5.34 (0.05) 3.31 (0.05) 1.42 (0.02) 0.31 (0.02)
APOE2 5.04 (0.10)* 2.74 (0.09)* 1.48 (0.04) 0.30 (0.04)
APOE4 5.39 (0.09)** 3.35 (0.08)** 1.45 (0.03) 0.30 (0.03)
SCARB 1
CC 5.31 (0.07) 3.27 (0.06) 1.42 (0.03) 0.30 (0.03)
CT 5.29 (0.06) 3.23 (0.05) 1.42 (0.02) 0.32 (0.02)
TT 5.25 (0.10) 3.09 (0.09) 1.49 (0.04) 0.29 (0.04)
PPARα
CC 5.28 (0.04) 3.21 (0.04) 1.42 (0.03) 0.31 (0.02)
CG 5.54 (0.18) 3.43 (0.16) 1.41 (0.02) 0.36 (0.07)
Data adjusted by age and body mass index.
APOE2 - carriers of the ε 2/2 and ε 2/3 genotype, APOE3 - carriers of the ε 3/3
genotype, and APOE4 - carriers of the ε 3/4 and ε 4/4 genotype.
* p <0.05 compared with APOE3 genotype; ** p <0.05 compared with APOE2
genotype; # p <0.05 compared with SCARB1genotype CC; ## p <0.05 compared
with PPARα genotype CC.
Abrevations: APOE apolipoprotein E, HDL-C high density lipoprotein cholesterol,
LDL-C low density lipoprotein cholesterol, LnTG logarithmically transformed
triglycerides, PPARα Peroxisome proliferator-activated receptor-alpha, SE
Standard Error, SCARB1 Scavenger Receptor Class B Type 1, TC
total cholesterol.
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with respect to the APOE, SCARB1, PPARα genotypes
are shown in Table 3. Men and women with the APOE2
genotype had the lowest level of TC and LDL-C. Mean
values of TC and LDL-C were the highest in men and
women with the APOE4 genotype; however, they did not
differ significantly from the mean values of those lipids
in the APOE3 genotype carriers. Men with the APOE2
genotype had significantly higher levels of TG than those
with the APOE3 genotype. There were no significant dif-
ferences in the levels of TG in women and in the levels
of HDL-C in either gender among different genotype
groups.
In men, the SCARB1 TT genotype carriers had a sig-
nificantly higher levels of LDL-C than men with the
SCARB1 genotype CC (Table 3). Moreover, men with
the SCARB1 CT genotype had lower levels of TG in
comparison to CC genotype carriers. No significant dif-
ferences in the levels of HDL-C between different
SCARB1 genotype groups were found in men. Serum
lipid levels were not associated with SCARB1 genotypes
in women.Men with the PPARα genotype CG had higher levels
of triglycerides than did CC genotype carriers (Table 3).
In women, no significant differences in serum lipid levels
were found between different PPARα genotypes.
Multivariate logistic regression analysis was performed
to identify the associations of the APOE, SCARB1,
PPARα genotypes with the prevalence of dyslipidemias
in the study population (Table 4). After adjustment for
age, body mass index, physical activity and alcohol con-
sumption, the odds of having high TC and high LDL-C
levels were lower in women with the APOE2 genotype
compared to APOE3 genotype carriers (respectively
OR=0.52; p=0.006 and OR=0.35; p<0.001). In men, the




High TC High LDL-C Reduced HDL-C Elevated TG
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
MEN
APOE
APOE3 1 1 1 1
APOE2 0.60 (0.33-1.02) 0.60 (0.35-1.02) 1.56 (0.85-2.85) 1.36 (0.79-2.34)
APOE4 1.04 (0.58-1.88) 1.37 (0.74-2.54) 1.98 (1.05-3.74) 1.50 (0.84-2.67)
SCARB 1
CC 1 1 1 1
CT 1.20 (0.77-1.84) 1.09 (0.69-1.72) 0.76 (0.45-1.26) 0.50 (0.31-0.79)
TT 1.67 (0.89-3.23) 1.91 (0.98-3.73) 0.75 (0.36-1.58) 0.66 (0.35-1.26)
PPARα
CC 1 1 1 1
CG 1.12 (0.47-2.66) 0.79 (0.34-1.84) 0.52 (0.15-1.84) 2.67 (1.15-6.16)
WOMEN
APOE
APOE3 1 1 1 1
APOE2 0.52 (0.32-0.83) 0.35 (0.22-0.57) 0.62 (0.34-1.11) 0.97 (0.57-1.66)
APOE4 0.84 (0.54-1.30) 0.96 (0.62-1.49) 0.78 (0.48-1.29) 1.10 (0.69-1.76)
SCARB 1
CC 1 1 1 1
CT 1.18 (0.80-1.74) 1.14 (0.78-1.68) 1.43 (0.92-2.23) 1.16 (0.76-1.77)
TT 1.39 (0.83-2.33) 0.83 (0.50-1.37) 0.82 (0.43-1.53) 1.03 (0.58-1.80)
PPARα
CC 1 1 1 1
CG 1.71 (0.77-3.80) 1.95 (0.86-4.43) 1.23 (0.54-2.84) 0.82 (0.34-1.96)
Data adjusted by age, body mass index, physical activity, and alcohol consumption.
APOE2 - carriers of the ε 2/2 and ε 2/3 genotype, APOE3 - carriers of the ε 3/3 genotype, and APOE4 - carriers of the ε 3/4 and ε 4/4 genotype.
Abrevations: APOE apolipoprotein E, Elevated TG triglycerides level >1.7 mmol/L, High TC total cholesterol ≥5.0 mmol/L, High LDL-C low density lipoprotein
cholesterol ≥3.0 mmol/L, PPARα Peroxisome proliferator-activated receptor-alpha, Reduced HDL- C high density lipoprotein cholesterol level for men<1.0 mmol/L
and for women <1.20 mmol/L, SCARB 1 Scavenger Receptor Class B Type 1.
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higher in APOE4 genotype carriers than in those with
the APOE3 genotype (OR=1.98; p=0.035). The asso-
ciations of the SCARB1 and PPARα genotypes with
dyslipidemia were found only in men (Table 4). The
odds of having elevated TG levels was statistically
lower in the SCARB1 genotype CT carriers as com-
pared to men with the SCARB1 genotype CC (OR=
0.50; p=0.003). In men, carriers of the PPARα genotype
CG had higher OR of elevated TG levels versus carriers
of the PPARα genotype CC (OR=2.67; p=0.022).
Discussion
The overall pattern of the allele frequency distribution
analyzed in the Lithuanian population was similar to
other European populations. Nevertheless, some differences
in APOE allele frequencies were observed between NorthernEuropean countries and Lithuania. Namely, a lower preva-
lence of the APOE ε2 allele and a higher prevalence of the
APOE ε4 allele was found in Finland (4% and 20% respect-
ively) [23], Denmark (8% and 17% respectively) [24] and
Sweden (7% and 17% respectively) [25], as compared to the
Lithuanian population. Findings from 45 populations around
the world have shown that the frequency of the APOE ε4 al-
lele appears to be higher in northern regions of Europe (the
Nordic countries, Scotland, Germany, and the Netherlands)
than in southern regions (Switzerland, Tyrol, France, Italy,
and Spain) [26]. The distribution of the APOE allele in
Lithuania was more comparable to Southern European
populations. The studies demonstrated a lower risk of
CHD in ε2 carriers and a higher risk in ε4 carriers as com-
pared to ε3 homozygotes [8,27,28]. Bearing in mind the
facts above, only a modest risk of CHD should be
expected in Lithuania, although the mortality from CHD
Smalinskiene et al. Lipids in Health and Disease 2013, 12:120 Page 5 of 8
http://www.lipidworld.com/content/12/1/120in the population of Lithuania is one of the highest in
Europe [1].
Many studies suggested that variation of the APOE
gene was associated with variations of lipid levels
[7,8,24,25,27]. In line with the findings of other re-
searchers, we found that APOE2 genotype carriers had
the lowest levels of TC and LDL-C. The mechanism of
this effect probably involves decreased conversion of
VLDL into LDL observed in ε2 carriers [5,6]. More effi-
cient catabolism of chylomicrons and VLDL-remnants,
increased intestinal cholesterol absorption, and reduced
LDL-receptor activity was shown in ε4 carriers resulting
in higher levels of TC and LDL-C when compared to ε2
and ε3 allele carriers. Thus, a high frequency of the ε2
allele would appear to predict a favorable lipid profile in
the Lithuanian population. Moreover, positive changes
in nutritional habits of Lithuanians occurred over the
last decades of the post-communist transition period
and has contributed to the decrease in mean TC and
LDL-C levels [3,4]. However, the prevalence of other car-
diovascular disease risk factors, such as hypertension,
smoking and obesity, remains very high in Lithuania
[29]. It is obvious, that the risk of cardiovascular disease
is determined by multiple genetic and environmental
factors, and the impact of one gene is very limited. On
the other hand, men with the APOE2 genotype had
higher levels of TG than those with the APOE3 geno-
type. It was revealed that APOE2 binds poorly to lipo-
protein receptors leading to accumulation of chylo
micron and VLDL-remnants [6]. The higher TG levels
in APOE2 genotype carriers may attenuate the cardio-
protective effects of lower LDL-C [24]. The APOE geno-
type also affected HDL-C level. Our data showed the
higher odds of reduced HDL-C levels in men with the
APOE4 genotype as compared to those with the APOE3
genotype. Other studies also found lower HDL-C in ε4
allele carriers [7,24,25].
Much less is known regarding the role of SCARB1 in
humans, although several studies have reported that the
SNP of SCARB1 (rs5888) is associated with the lipid
profile and the development of CHD [9,12,13]. The fre-
quencies of the SCARB1 alleles in our population were
similar to frequencies that have been reported for
French and North American populations [30]. Our data
indicated that in men the carriers of the SCARB1 geno-
type CT had two-fold lower odds of high TG levels than
the carriers of the genotype CC. The tendency of lower
odds of high TG levels was shown also for the SCARB1
genotype TT carriers. Insufficient numbers of individuals
with the SCARB1 genotype TT in the study population
may probably explain why the odds did not reach statis-
tical significance. Men with the SCARB1 genotype TT
had a higher level of LDL-C as compared to SCARB1
genotype CC carriers. In contrast to our findings,Morabia A et al. found higher LDL-C in women with
the T allele [9]. We did not observe any association
between the SCARB1 genotype and dyslipidemia in
women. Several studies have shown that a rare T variant
was associated with an atheroprotective lipid profile in
men but not in women [9,13]. A previous study carried
out in Lithuania revealed that men aged 65–74 who
were carriers of the TT genotype had a higher level of
HDL-C and a lower risk of myocardial infarction as
compared to the CC genotype [31]. Gender and age-
specific effects on blood lipid profiles were also demon-
strated by other investigators [12,13,15]. Those studies
highlighted a protective T allele effect on HDL-C.
SCARB1 was identified as a physiologically important
HDL receptor; however, it is also a multiligand receptor
participating in the metabolism of other plasma lipopro-
teins [14]. The mechanism of the SCARB1 SNP rs5888
effect on the lipid profile remains not finally determined
because polymorphisms in this SNP does not lead to a
change in the amino acid sequence of the SCARB1 pro-
tein [9,14].
The prevalence of the PPARα G allele in our popula-
tion was lower as compared to the prevalence that has
been reported in other studies [20,22,32]. The results
from a Quebec study indicated that carriers of the G al-
lele may be at increased risk of abdominal obesity,
hypertriglyceridemia, and low HDL-C levels [20]. The
Framingham Offspring Study found that the G allele was
associated with increased plasma concentrations of TC,
LDL-C, and apoB [22]. In our study, the PPARα CG ge-
notypes were associated with elevated TG levels only in
men. It is known that PPARα stimulates proteins of the
transport and binding of fatty acids. Moreover, it regu-
lates genes involved in fatty acid oxidation [16,19]. Tak-
ing this in mind it is reasonable to believe that the
functional L162V polymorphism located in the DNA-
binding domain of the PPARα gene may have an effect
on lipid metabolism, particularly on TG levels [33].Study strength and limitations
A major strength of our study is an investigation of a na-
tionally representative random sample of the Lithuanian
population, allowing assessment of the frequencies of al-
leles related to lipid levels. However, this study had some
limitations. The cross-sectional study design did not
allow us to consider the effects of all possible genetic
and environmental factors and their interactions on lipid
levels. Another issue involves the unhealthy diet of the
majority of the Lithuanian population. A high intake
of fats, especially saturated fats, might influence lipid
levels and have an important interaction with the geno-
types under study. Furthermore, we did not have data
about hormone replacement therapy in postmenopausal
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Conclusions
Our data suggested a gender difference of the associa-
tions between APOE, SCARB1, PPARα genotypes and
lipid levels. In men, the APOE4 genotype and the PPARα
genotype CG were correlated with an atherogenic lipid
profile while the SCARB1 genotype CT had an athe-
roprotective effect on lipid levels. In women, APOE2
carriers had the lowest odds of high LDL-C. Further
studies, particularly evaluating genetic-environmental
interactions on lipid levels, are necessary to confirm our
established associations.
Materials and methods
Study design and sample
The cross-sectional health survey was carried out in five
randomly selected municipalities of Lithuania. The ran-
dom sample was obtained from lists of inhabitants aged
25–64. Health examinations were conducted for 1739
participants (58% of the eligible sample). From these,
1030 individuals (425 men and 605 women) had the
APOE, SCARB1 and PPARα genotypes determined. We
excluded 5 subjects taking lipid lowering medications
from our analysis (1 man and 4 women). Also we ex-
cluded 34 subjects (13 men and 21 women) with the
rare APOE ε2/4 genotype from the analysis of associa-
tions between the APOE genotypes and lipid levels.
APOE, SCARB1 and PPARα genotyping
For DNA extraction, blood samples were collected from
each individual in ethylenediaminetetraacetic (EDTA)
tubes during their health examination. DNA was ex-
tracted from peripheral blood leukocytes using a reagent
kit (NucleoSpin Blood L Kit; Macherey & Nagel, Düren,
Germany).
Two single-nucleotide polymorphisms (SNPs) of APOE
gene (rs429358 and rs7412) were assessed using commer-
cially available genotyping kit C___3084793_20 and
C____904973_10. SNP of SCARB1 gene (rs5888) was
assessed using commercially available genotyping kit
C_7497008_1_ and SNP of PPARα gene (rs1800206) was
assessed using commercially available genotyping kit
C___8817670_20 (Applied Biosystems, Foster City, CA,
USA). We used the Applied Biosystems 7900HT Real-
Time Polymerase Chain Reaction System for detecting the
SNPs. The cycling program started with heating at 95°C
for 10 min, followed by 40 cycles (at 95°C for 15 s and at
60°C for 1 min). Allelic discrimination was carried out
using the software of Applied Biosystems.
Three APOE genotype groups were analyzed in this
study: APOE2 (carriers of the ε 2/2 and ε 2/3 genotype),APOE3 (carriers of the ε 3/3 genotype), and APOE4 (car-
riers of the ε 3/4 and ε 4/4 genotypes).
Laboratory analyses and anthropometric measurements
Blood samples for lipids measurements were taken in
the morning after fasting at least 12 hours. TC, LDL-C,
HDL-C, and TG levels were determined by an automatic
analyzer using conventional enzymatic methods. All la-
boratory analyses were made in the same certified la-
boratory. Quality control measures were followed for
estimation of lipid levels. Dyslipidemias were defined
using the following criteria: high TC level - serum TC≥5
mmol/L; high LDL-C level - serum LDL-C ≥3 mmol/L;
reduced HDL-C level - serum HDL-C for men <1.0
mmol/L and for women <1.2 mmol/L; elevated TG
level- TG >1.7 mmol/L [34].
The height of participants wearing no shoes was mea-
sured to the nearest centimeter with a stadiometer. The
body weight of participants wearing light indoor clothing
and no shoes was measured to the nearest 0.1 kg with
standardized medical scales. Body mass index (BMI) was
calculated as weight divided by height squared (kg/m2).
Obesity was defined as BMI≥30 kg/m2.
Assessment of physical activity and alcohol consumption
Information on physical activity and alcohol consump-
tion was gathered by a standard questionnaire. The
number of hours spent per week for physical activity at
work, travelling to and from work and at leisure time
was calculated. The questionnaire on alcohol consump-
tion contained questions about a type and frequency of
alcohol consumption and amount of alcohol consumed
at one occasion. The amount of alcohol consumed at
one occasion was recalculated into standard alcohol
units (SAUs) using the following formula: SAU =
amount (in liters) × strength of alcoholic drink (beer –
5%, wine – 12%, strong alcohol – 40%). One SAU equals
to 10 g of ethanol. Then the amount of SAUs consumed
during a month was calculated.
Statistical analysis
The data were analyzed with statistical software package
SPSS version 19.0 for Windows. All data were analyzed
in each gender separately. Continuous variables were
presented as mean values and standard error (SE). The
normality of distribution of continuous variables was
tested by Kolmogorov - Smirnov test. Only distribution
of triglyceride levels was skewed, and this variable was
logarithmically transformed to improve normality for
statistical testing. Analysis of variance with Bonferroni
multiple comparison tests were used to compare the
means of continuous variables across groups.
The mean values of TC, LDL-C, HDL-C and TG levels
by the APOE, SCARB1, PPARα genotypes were calculated
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physical activity and alcohol consumption.
The effects of the APOE, SCARB1, PPARα genotypes
on the prevalence of dyslipidemias were evaluated using
logistic regression analysis. All models were applied sep-
arately for men and women. Each genotype was included
into a separate model. The odds of dyslipidemias were
calculated with adjustment for age, body mass index,
physical activity and alcohol consumption.
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